Wyndham Hopkins Wilson MD

Physician

Room 4n115 Bldg 109000 Rockville PikeBethesda, MD 20892
Phone+1 240-760-6092

Dr. Wilson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wilson's full profile Already have an account?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1981 - 1984
Stanford University School of MedicineClass of 1981

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2019 - 2027
WV State Medical License 1985 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Start of enrollment: 1993 May 08
COMPLETED
PHASE2
Treatment and Natural History Study of Lymphomatoid Granulomatosis Start of enrollment: 1995 May 05
COMPLETED
PHASE2
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Start of enrollment: 1997 Jan 08
COMPLETED
PHASE2

Publications & Presentations

PubMed

Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma.
Max J Gordon, Hyoyoung Choo-Wosoba, Gonca Ozcan, Rahul Lakhotia, Elizabeth Hill
Blood Advances. 2026-08-25
1 citations
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.
Max J Gordon, Milos D Miljkovic, Paige Milhon, Rahul Lakhotia, Christopher Melani
Blood Advances. 2026-05-26
2 citations
Axes of biological variation in diffuse large B cell lymphoma.
Boya Wang, George Wright, Julius C Enssle, Xin Yu, James D Phelan
Cancer Cell. 2026-03-09

Journal Articles

End-of-Treatment and Serial PET Imaging Has Prognostic Value and Clinical Utility in Primary Mediastinal B-cell Lymphoma Following Dose-Adjusted EPOCH-R - Response to ...
Mark Roschewski, Wyndham H Wilson, Christopher Melani, Haematologica
A Multiprotein Supercomplex Controlling Oncogenic Signalling in Lymphoma
Maryknoll M Palisoc, Lisa M Rimsza, Stephen M Hewitt, Wyndham H Wilson, Matthias Holdhoff, Fayez Estephan, Nature

Abstracts/Posters

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...
Wyndham Wilson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term D...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Ibrutinib Add-on 'Almost Certainly' Saves Lives in DLBCLNovember 4th, 2021
Global Trial Eliminates Drugs, Pivots to New OnesOctober 23rd, 2020
Cancer Researchers Cross over to COVID-19 Clinical TrialsOctober 20th, 2020

Grant Support

Phase I And II Study Of BCL Family Inhibitors In LymphomaNational Cancer Institute2011
Randomized Phase II Study Of Borteozmibepoch-R In Mantle Cell LymphomaNational Cancer Institute2010–2011
Phase III Study Of R-CHOP V Da-Epoch-R With MicroarrayNational Cancer Institute2010–2011
Phase II Study Of Flavopiridol In Mantle Cell Lymphoma And DlbclNational Cancer Institute2010–2011
Phase I Study Of Bortezomib And Da-Epoch-R With Microarray In DlbclNational Cancer Institute2010–2011